P2RY12 and coronary artery disorder: Cangrelor is a reversible, parenteral, 3rd-generation non-thienopyridine P2Y12 ADPRB, which is indicated for combined antiplatelet therapy in patients undergoing PCI (both for ACS and stable CAD) who are not pre-treated with oral ADPRB [4].